ACE and COVID-19: Finally, a retrospective, multi-center study demonstrated a lower risk of COVID-19 mortality in inhospital patients with hypertension and hospitalized due to COVID-19 who received ACE inhibitor/ARB compared to those who did not receive an ACE inhibitor/ARB (adjusted HR, 0.37; 95% CI, 0.15 to 0.89) (55).